These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 25140626

  • 1. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA, Dzik C, Rathkopf D, Scher HI.
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [Abstract] [Full Text] [Related]

  • 2. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK, Kyprianou N.
    Adv Cancer Res; 2015 Aug; 127():123-58. PubMed ID: 26093899
    [Abstract] [Full Text] [Related]

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA, Yen AE, Weigel NL.
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [Abstract] [Full Text] [Related]

  • 4. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H.
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [Abstract] [Full Text] [Related]

  • 5. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 6. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I, Day TK, Tilley WD, Selth LA.
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [Abstract] [Full Text] [Related]

  • 7. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [Abstract] [Full Text] [Related]

  • 8. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Imamura Y, Sadar MD.
    Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
    [Abstract] [Full Text] [Related]

  • 9. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR, Hussain MH.
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [Abstract] [Full Text] [Related]

  • 10. Management of patients with castration-resistant disease.
    Pezaro C, Omlin A, Lorente D, de Bono J.
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1243-60, ix. PubMed ID: 24188261
    [Abstract] [Full Text] [Related]

  • 11. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N.
    J UOEH; 2016 Jun 01; 38(2):129-38. PubMed ID: 27302726
    [Abstract] [Full Text] [Related]

  • 12. Resistance to Hormonal Therapy in Prostate Cancer.
    Berruti A, Dalla Volta A.
    Handb Exp Pharmacol; 2018 Jun 01; 249():181-194. PubMed ID: 28353036
    [Abstract] [Full Text] [Related]

  • 13. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S, Arai Y.
    Nihon Rinsho; 2014 Dec 01; 72(12):2126-9. PubMed ID: 25518345
    [Abstract] [Full Text] [Related]

  • 14. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.
    Kim W, Ryan CJ.
    Cancer; 2015 Feb 01; 121(3):361-71. PubMed ID: 25236176
    [Abstract] [Full Text] [Related]

  • 15. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr 01; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 16. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
    Antonarakis ES, Chandhasin C, Osbourne E, Luo J, Sadar MD, Perabo F.
    Oncologist; 2016 Dec 01; 21(12):1427-1435. PubMed ID: 27628492
    [Abstract] [Full Text] [Related]

  • 17. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
    Eur Urol; 2014 Feb 01; 65(2):289-99. PubMed ID: 23957948
    [Abstract] [Full Text] [Related]

  • 18. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H, Garcia JA.
    Curr Opin Urol; 2012 May 01; 22(3):175-82. PubMed ID: 22472509
    [Abstract] [Full Text] [Related]

  • 19. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ, Milowsky MI, Whang YE.
    Clin Pharmacol Ther; 2015 Dec 01; 98(6):582-9. PubMed ID: 26331358
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
    Galletti G, Leach BI, Lam L, Tagawa ST.
    Cancer Treat Rev; 2017 Jun 01; 57():16-27. PubMed ID: 28527407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.